Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer

Jeong Ho Moon, Yoshiyuki Fujiwara, Motohiro Hirao, Hiroshi Imamura, Yutaka Kimura, Kazumasa Fujitani, Junya Fujita, Shigeyuki Tamura, Shuji Takiguchi, Masahiko Yano, Masaki Mori, Yuichiro Doki

研究成果: Contribution to journalArticle査読

4 被引用数 (Scopus)

抄録

Aim: This prospective randomized study compared the survival of patients with stage IB-IIIA gastric cancer treated with surgery alone or surgery followed by adjuvant chemotherapy. Patients and Methods: Patients with pathological stage IB-IIIA disease were randomly assigned to the following groups: surgery alone (n=116), or surgery followed by adjuvant chemotherapy with 5-fluorouracil, doxifluridine, or uracil-tegafur for 12 months (n=113). Results: The overall survival rate was 86.1% in the adjuvant group and 78.5% in the surgery-alone group. The overall survival rate did not significantly differ between the adjuvant-chemotherapy and surgery-only groups (p=0.163). In the subgroup analyses, patients with stage II disease and those receiving uracil-tegafur treatment in the adjuvant group showed significantly better prognosis than those in the surgery-alone group (p=0.036 and 0.005, respectively). Conclusion: This study did not find a significant survival benefit to be associated with adjuvant chemotherapy with fluoropyrimidines in patients with stage IBIIIA gastric cancer. However, it may be effective for patients with stage II disease. Additionally, uracil-tegafur is a promising agent for adjuvant chemotherapy of gastric cancer if S-1 is not available because of its toxicity.

本文言語英語
ページ(範囲)3061-3067
ページ数7
ジャーナルAnticancer research
37
6
DOI
出版ステータス出版済み - 6 2017
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「Randomized controlled trial of adjuvant chemotherapy with fluoropyrimidines versus surgery-alone for gastric cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル